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ABSTRACT 1 
Background: Administration of medications to paediatric patients is challenging as many 2 
drugs are not commercially available in appropriate dosage forms and dosage strength. 3 
Consequently, these drugs are prepared extemporaneously as oral liquid (OL) using 4 
marketed tablets or capsules. Unfortunately, these extemporaneous preparations often have 5 
no documented stability studies which impact on the safety of these preparations. An 6 
alternative extemporaneous solid formulation such as fast dispersible tablets (FDTs) can 7 
offer enhanced stability as well as dosing flexibility as these can be administered as 8 
orodispersible tablets or as reconstituted suspension/solution. While FDTs are available 9 
increasingly as patient friendly oral dosage forms and their simple method of manufacture 10 
can be applied to extemporaneous formulations, such applications have not been explored 11 
to date.  12 
Objective: The use of extemporaneous captopril OL formulations in Irish hospitals was 13 
surveyed and the stability of the most commonly used captopril formulation was 14 
investigated and was compared with that of a novel extemporaneous fast dispersible tablet 15 
(FDT) formulation.  16 
Methods: A survey was carried out regarding the use of captopril OL formulations in 120 17 
hospitals in the Republic of Ireland. The stability of the most commonly used formulation 18 
was compared against a novel extemporaneous captopril FDT preparation. Captopril 19 
content of the formulations was measured by HPLC analysis. Formulations were also 20 
monitored for changes in appearance, colour, odour and pH (OLs).  21 
Results: The survey showed that extemporaneously prepared captopril OLs were 22 
extensively used particularly in specialist childrens hospital. The most commonly used 23 
preparation was Keltrol® based oral suspension. Analysis of these OL preparations showed 24 
the OLs to be stable up to day 7 but captopril concentration decreased to 72-84% at day 14 25 
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and 59-68% at day 56 and this was accompanied by a pungent odour suggestive of 26 
captopril oxidation. In contrast FDT formulations demonstrated longer stability with 96% 27 
of captopril present at day 56.   28 
Conclusions: The results of this study support only a 7 day stability for the currently 29 
dispensed captopril OL in Irish hospitals. In contrast a long stability of at least 56 days was 30 
shown for the FDTs. The FDTs present an alternative and convenient oral solid 31 
extemporaneous preparation for captopril and potentially for other extemporaneous 32 
paediatric medications. 33 
 34 
Key words: captopril, paediatric, extemporaneous compounding, unlicensed preparations, 35 
oral liquid, fast dispersible tablets  36 
 37 
INTRODUCTION 38 
The majority of oral preparations are available as solid dosage forms such as tablets and 39 
capsules which present advantages such as patient convenience and compliance and high 40 
chemical and microbiological stability compared to liquid dosage forms.
1
 However, 41 
conventional tablets are inappropriate for use by certain patient populations including 42 
elderly and paediatric patients as tablets are designed to be swallowed and corresponding 43 
liquid preparations are often not commercially available due to many factors including lack 44 
of market size.
2-4
 Therefore pharmacists in both hospital and community settings are often 45 
challenged to extemporaneously prepare oral liquid (OL) preparations to allow ease of dose 46 
administration in particular to paediatric patients. It is reported that such extemporaneous 47 
OLs constitute about 40% of preparations administered to paediatric patients.
3
 Captopril, an 48 
ACE inhibitor, is commonly used to treat paediatric hypertension and heart failure.
5-9
 It is 49 
used as an unlicensed preparation in children as captopril is only approved for use in adults. 50 
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Captopril is generally available in doses ranging 12.5 mg - 100 mg for administration to 51 
adults. The doses recommended for children are generally lower than 12.5 mg; the BNF for 52 
Children (2012-13) recommends a maximum dose of 300 mcg/kg daily for neonates and 6 53 
mg/kg daily for children aged 1 month–12 years, administered in divided doses. Since the 54 
paediatric dose is lower than the dose administered by adults, paediatricians have to 55 
instruct parents to crush tablets and administer the medication mixed in food or else 56 
instruct pharmacists to compound extemporaneous suspensions which offer advantages of 57 
titratable individualised doses.
5,11,12
 Extemporaneous formulations are usually prepared 58 
from commercially available oral solid dosage forms by simply crushing tablets or opening 59 
capsules and subsequent addition of water or other diluents. In certain cases, unlicensed 60 
preparations can also be procured from a „specials‟ manufacturer or imported from outside 61 
the EU. However in most cases limited stability data exists for these preparations.
3,4,6
 In 62 
addition as there is often no consistency in compositions from various hospitals, health 63 
centres, pharmacies and specials manufacturers, these raise issues regarding the efficacy 64 
and toxicity of these preparations.
8-10 
65 
 
66 
As a solid, captopril is stable, however in solution it undergoes free radical oxidation to 67 
yield captopril disulphide as the major degradation product.
13
 This degradation is complex, 68 
concentration and pH dependent with highest stability at pH 3.5.
13
 The aqueous stability of 69 
captopril was reported to be determined by the quality of the water. When prepared in tap 70 
water from Edmonton, Alberta, captopril was reported to be stable for 27 days at 5°C, 71 
while in tap water from Rochester, New York, captopril was extremely unstable.
14-17
 In 72 
sterile buffered water (pH 3 and pH 5), 1 mg/mL captopril solution made from triturated 73 
tablets was found to be stable for at least 28 days at 4
o
C.
18,19
 Enhanced storage stability of 74 
>56 days at 4
o
C was reported when antioxidants such as ascorbic acid or sodium ascorbate 75 
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was added to aqueous solution of captopril.
2,6,10,20,21
 On the contrary, Berger et al
22
 reported 76 
that solutions of commercial captopril tablets in purified water containing ascorbate and/or 77 
EDTA-Na showed limited stability of less than one month, related to the presence of metal 78 
ions in the tablets to catalyse oxidation.   79 
A major issue with extemporaneous OL captopril preparation is its stability profile and the 80 
variety of formulations which are used between different hospitals and dispensing centres 81 
in addition to „specials‟ preparations which are also dispensed. This may result in patients 82 
dispensed with formulations which are inconsistent regarding their stability and shelf-life 83 
and therefore efficacy and toxicity.
8,9,23
  84 
 85 
Oral powders individually packaged or filled into capsules have been used as an alternative 86 
extemporaneous preparations for administration mixed with feeding liquid or appropriate 87 
food and as the drug is in solid state, these dosage forms are more stable and generally are 88 
given a shelf life of 28 days. However such formulations are not favoured in England, 89 
Ireland, Norway and Sweden where liquid formulations are predominantly used.
6
 Fast 90 
dispersible tablets (FDTs), in particular oro-dispersible tablets introduced for patients with 91 
difficulty in swallowing tablets can offer an alternative extemporaneous formulation with 92 
various advantages such as prolonged stability as the drug is in solid state, dosing 93 
flexibility as reconstituted suspensions or solutions for infants or enteral feeding or as oro-94 
dispersible tablet to elderly patients and older children. Despite their popularity as 95 
commercial preparations and their ease of manufacture by a one-step direct compression 96 
process, these formulations have not been explored for extemporaneous dispensing. With 97 
the availability of a variety of directly compressible (DC) sugars and single station tablet 98 
press, such formulations can be easily prepared in a hospital pharmacy setting.  99 
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The objective of this study was to survey the type of captopril extemporaneous 100 
formulations that are dispensed in hospitals in the Republic of Ireland and to evaluate the 101 
stability of the most commonly prepared extemporaneous captopril formulation. A novel 102 
captopril fast dispersible tablet formulation was extemporaneously formulated as an 103 
alternative preparation and its stability was compared with that of the most commonly 104 
prepared captopril OL formulation.  105 
 106 
MATERIALS AND METHODS 107 
Materials 108 
Captopril was purchased from Sigma-Aldrich Ireland. Captopril tablets; Capoten® 25 and 109 
50 mg, Captor® 50 mg, xanthan gum 0.4% w/v (Keltrol®, Victoria Pharm.) were 110 
purchased from United Drug Ireland. All analytical solvents and reagents were of HPLC 111 
grade. Mannitol 200 (Parteck®) was purchased from Merck KGaA (Norman Lauder, 112 
Dublin, Ireland), Kollidon® CL-SF was a gift from BASF, Cheshire, UK and magnesium 113 
stearate was received from JMB, UK.  114 
 115 
Survey of hospitals  116 
A survey was carried out to evaluate extent of dispensing of captopril oral liquid (OL) 117 
formulations in approximately 120 hospitals in the Republic of Ireland. The questionnaire 118 
was designed to determine the route of administration i.e. oral or nasogastric, the source i.e. 119 
whether extemporaneously prepared or procured from external source “specials 120 
manufacturer”, and the identity of the external source. In addition, the survey asked for any 121 
data available on the composition and properties of the extemporaneously prepared OLs in 122 
the hospitals; vehicle, other excipients, pH, stability and shelf life. 123 
 124 
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Extemporaneously prepared captopril OLs 125 
Captopril OLs were extemporaneously compounded at three strengths of 1, 2.5 and 10 126 
mg/mL in Keltrol®. Capoten® 50 mg tablets were used to formulate the 1 and 2.5 mg/ mL 127 
suspensions while Captor® 50 mg tablets were used for the 10 mg/mL suspensions. 128 
Captopril tablets, Captor® or Capoten® were ground to a fine uniform powder using a 129 
mortar and pestle. A small amount of the Keltrol® was added to form a paste, before 130 
adding further portions and transferring to a 100 ml volumetric flask. The formulation was 131 
made up to final volume of 100 mLs and transferred to an amber glass bottle. Formulations 132 
were prepared in triplicates and stored in amber glass bottles at 2-6 
o
C. The formulations 133 
were analysed at days 0, 1, 4, 7, 14, 21, 28 and 56 for “opened” bottles and at days 0, 1, 14, 134 
28, 56 for “unopened” bottles. The formulations were shaken vigorously prior to sampling 135 
to ensure a homogenous suspension. 136 
  137 
Formulation of extemporaneous captopril FDTs  138 
Captopril FDTs were prepared at two strengths, 2.5 mg and 10 mg, using a simple blending 139 
of the formula outlined in Table I and a direct compression tableting process.
24,25
 Briefly, 140 
an appropriate number of Captor® 25mg tablets were powdered and blended with Mannitol 141 
200, Kollidon® CL-SF and raspberry flavour for 5 minutes in a plastic bag; subsequently 142 
magnesium stearate was added and blended for a further 2 minutes. Tablets were 143 
compressed using a Piccola tablet press at a low speed of 7 rpm and compression force of 144 
10 kN. Tablets were stored in securitainers at room temperature until sampled for analysis. 145 
 146 
Characterisation of FDTs 147 
Uniformity of tablet weight was carried on n=10 tablets, taken randomly and weighed 148 
individually on a Sartorius balance, Model CP225D, Bradford, MA, USA. The average 149 
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weight of the tablets +/- standard deviation was calculated. Hardness of the tablets was 150 
carried out individually on n=3 tablets using a pre-calibrated PTB 411E Tablet hardness 151 
tester (PharmaTest Germany). Individual tablets was placed between the jaws and the force 152 
(Newtons) needed for the diametrical crushing of the tablets was recorded (BP 2009)
26
. The 153 
average hardness ± standard deviation was calculated. Disintegration tests on FDTs (n=3) 154 
were performed in deionised water maintained at 37˚C ± 2˚C, using a pre-calibrated 155 
Pharmatest PTZ Auto, PTFE Disintegration tester, (PharmaTest Germany). One ODT at a 156 
time was placed into the disintegration apparatus and the time taken (seconds; s) for the 157 
tablet to fully disintegrate was recorded. The average DT +/- standard deviation were 158 
calculated.  159 
 160 
pH testing, visual appearance and organoleptic property  161 
The pH of all formulations was measured in triplicates using a calibrated pH meter 162 
(CyberScan 510, Lennox, Dublin, Ireland) immediately after their preparation and on each 163 
sampling days. 164 
The colour of the captopril OL was analysed by observing a sample of the OL in a clear 165 
beaker against a black background. The odour of the OLs was recorded. Keltrol® was used 166 
as the control. FDTs were visually observed for appearance and colour.  167 
 168 
HPLC analysis of captopril formulations 169 
On each sampling day, 100 µl of the OL formulations was withdrawn for analysis of 170 
captopril content by the stability indicating HPLC method as described in the BP 2009 for 171 
“Captopril oral solution, related substances”26. Samples were diluted with an appropriate 172 
volume of mobile phase consisting of 0.5: 500: 500 mixture of orthophosphoric acid, water 173 
and methanol and were analysed using a Perkin Elmer HPLC system (PE Series 200) 174 
Ac
ce
pte
d M
an
us
cri
pt 
Cl
ini
ca
l T
h
rap
eu
tic
s
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
8 
 
equipped with “Total Chromatogram Navigator” software and UV detector adjusted at 220 175 
nm. The stationary phase was a Waters Spherisorb® C8 column (5 µm particle size, 4.6 x 176 
250 mm [PSS831815]). A flow rate of 1.0 mL/min was used.  Results were statistically 177 
analysed using Student‟s t-test, with a statistically significant difference represented by a p 178 
value less than 0.05. 179 
 180 
RESULTS  181 
Identification of hospitals and Data collection 182 
The survey questionnaire was sent to a total of 120 hospitals in the Republic of Ireland. A 183 
response rate of 79% was obtained. Of these, 8 hospitals dispensed extemporaneous 184 
captopril liquid formulations for oral or nasogastric use. In 6 of the 8 hospitals, captopril 185 
liquid formulations used were either compounded in-house or imported from a “specials” 186 
manufacturer. One hospital used only imported “specials” formulations while another only 187 
used extemporaneously compounded formulations. 188 
The unlicensed "specials” captopril liquid formulations used varied in source between the 189 
hospitals and were from Specials Lab, Martindale, Nupharm Labs and Nova Laboratories. 190 
One hospital used a formulation of captopril liquid by Bristol-Myers Squibb (Australia) 191 
which is licensed in Australia only. 192 
The survey showed that in the previous 12 months (2009/2010) one hospital catering 193 
specifically for sick children dispensed “hundreds” of captopril liquid for both oral and 194 
nasogastric use while the other hospitals dispensed captopril liquid for oral use, 2 of which 195 
also dispensed it for nasogastric use to <10 patients. 196 
  197 
Of the 8 hospitals dispensing extemporaneous captopril preparations in the Republic of 198 
Ireland, 7 hospitals, including the hospital catering for sick children, dispensed 199 
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compounded captopril OLs which varied in their source of captopril tablets as well as the 200 
diluent used. A total of 3 formulations were used; 6 hospitals powdered and dissolved 201 
captopril tablets, Captor® 25mg tablets in Keltrol® (xanthan gum 0.4 % w/ v), one hospital 202 
used Capoten® 25mg tablets, powdered and dissolved in water, ascorbic acid and Keltrol® 203 
and one hospital suspended powdered Capoten® 25mg tablets in OraPlus® and 204 
OraSweet®. None of the 8 hospitals dispensed captopril dissolved in water alone for oral 205 
use although this may be used for nasogastric administration.  206 
The stability and shelf life of the captopril OLs also varied. The captopril “specials” 207 
formulations used had shelf lives of 1-3 months,
10
 whereas extemporaneous OLs were 208 
given a shelf-life of 7-8 days when stored at 2-6
o
C. The hospital using ascorbic acid in the 209 
vehicle allowed a shelf life of 28 days. Apart from the Bristol-Myers Squibb formulation, 210 
no other manufacturer or hospital had conducted comprehensive stability studies on their 211 
finished OL product to support the stated shelf-life of 28 days.
9
 212 
 213 
Although the majority of extemporaneous captopril OLs used in the Irish hospitals are 214 
prepared using Keltrol® based diluents and hence are assigned a 7 day stability, there is a 215 
lack of safety and efficacy data available to support its use.
27
 As one of the aims of the 216 
present study, the stability evaluation of this most commonly extemporaneously 217 
compounded captopril OL was measured and was compared with an alternative oral solid 218 
extemporaneous preparation of captopril, a fast dispersible tablet.  219 
 220 
Stability of extemporaneously prepared captopril OLs 221 
pH profile of captopril OLs 222 
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The pH of all captopril OLs in Keltrol® was found to be <4 (Fig 1) and was inversely 223 
proportional to the captopril concentration. Over the 56 days studied, the pH of the 224 
captopril OLs increased slightly by 0.057-0.12 pH unit.  225 
 226 
Odour and colour of captopril OLs  227 
The odour of 1 and 2.5 mg/mL captopril OLs was slightly sulphurous, whilst the 10 mg/mL 228 
samples had a noticeably acidic odour. After 7 days the intensity of smell increased. At day 229 
14 a pungent smell was apparent and this increased in intensity with increase in captopril 230 
concentration. This odour remained intense over the 56 days of the study, making the 231 
formulations unpalatable. No change in colour of the captopril OL was observed 232 
throughout the 56 days of the study. Keltrol® diluents also remained colourless and 233 
translucent throughout the course of this study.  234 
 235 
Stability of captopril oral liquid 236 
The concentration of captopril present in the OLs was greater than 90% of the initial 237 
amount at days 1, 4 and 7, regardless of the captopril concentration (Fig 2). At day 14, the 238 
captopril concentration in the OLs fell below 90% for all captopril strengths. The decrease 239 
in the captopril concentration was dose dependent; the 1 mg/mL showed a lower captopril 240 
concentration of 80%, while at the higher doses of 2.5 mg/mL and 10.0 mg/mL the 241 
captopril concentrations were higher at 86%. The captopril concentration of the OLs 242 
continued to decrease over time, the decrease being higher at the lowest concentration. At 243 
day 56, the amount of captopril was 57%, 59% and 68% respectively in the 1, 2.5 and 10 244 
mg/mL OLs. Interestingly, a lower rate of degradation was observed for captopril OLs over 245 
the first 28 days from unopened bottles although at day 56, the extent of captopril 246 
degradation was found to be similar for OLs from unopened and opened bottles (Fig 3a-c).  247 
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Stability of extemporaneously prepared captopril FDTs 248 
FDTs formulated showed no sticking and capping and were found to be uniform in weight 249 
with a low variability of < 2%. The hardness of the 2.5 mg captopril FDTs was higher 250 
compared to the 10 mg captopril FDT (Table II). The hardness of the tablets did not change 251 
significantly over the 56 days. The FDTs disintegrated rapidly in less than 32 seconds. The 252 
DTs of the FDTs was found to decrease particularly over the first 15 days for both, 2.5 mg 253 
and 10 mg FDTs. No change in appearance or colour of FDTs was observed over the 56 254 
days.  255 
 256 
At day 1, the captopril content of the FDTs was high at 98% of starting captopril, similar to 257 
the captopril concentration (92-99%) detected in the OL of various concentrations (Fig 4). 258 
Captopril FDTs showed higher stability compared to corresponding captopril OL 259 
formulations.  Interestingly, no significant decrease (p >0.05) in the captopril concentration 260 
for the 10 mg captopril FDTs was observed over the 56 day stability period, while the 261 
captopril concentration of  the 10 mg/mL OL decreased significantly to 68.1% at day 56. 262 
The amount of captopril of the 2.5mg FDTs decreased from 98.7% at day 1 to 86.4% at day 263 
28. Subsequently no significant (p>0.05) decrease in captopril concentration was observed. 264 
As expected a larger decrease in captopril concentration to 59.2% was observed at day 56 265 
for the corresponding captopril OL formulation.  266 
 267 
DISCUSSION 268 
The survey carried out in 120 hospitals in the Republic of Ireland showed that 8 hospitals 269 
which dispense captopril OL formulations were dispensing various captopril OLs, 270 
extemporaneously prepared by the hospital pharmacists or procured from „specials 271 
manufacturers‟. The variations in extemporaneous formulations used between and within 272 
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individual hospitals are a concern as previously Mulla et al
8,9
 reported that unlicensed 273 
captopril formulations were not bioequivalent to each other and not bioequivalent to the 274 
licensed tablet form. This raises concern over optimal captopril dosing and may give rise to 275 
potential toxicity.
18
 Therefore substitution of one formulation with another should be 276 
carried out with care and may require increased monitoring. Additionally, once the patients 277 
are discharged, their supply of captopril OL formulations may change as they then receive 278 
their captopril OLs from their community pharmacies. Of the 8 hospitals dispensing 279 
extemporaneous captopril OLs, only two hospitals would contact the relevant community 280 
pharmacy to support continued use of the OL captopril preparations dispensed by the 281 
hospital. 282 
 283 
Another important variation is the stability and shelf life of the various extemporaneous OL 284 
captopril formulations. “Specials” OL formulations had a longer shelf of 1-3 months10 285 
compared to the extemporaneously prepared OL formulations dispensed in hospitals that 286 
were given a shelf life of 7-8 days when stored at 2-6
o
C. In the present study our data 287 
support a 7 day stability of the most commonly prepared captopril OL in Irish hospitals, 288 
irrespective of the concentration of captopril. After day 7 the captopril content decreased 289 
significantly over the 56 days period. Of importance however is that the intervals at which 290 
the stability of the captopril OLs was evaluated does not simulate the “in use” opening 291 
frequency which would be daily as a multi-dose regimen. Captopril OL bottles that were 292 
opened at much lesser intervals „unopened bottles‟ showed a lower rate of degradation. An 293 
increase in opening frequency of the bottles such as during in use by the patient most 294 
probably decreases the shelf life of captopril OLs related to the increased exposure to 295 
atmospheric oxygen. 296 
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A small increase in pH of the OLs and an increase in the intensity of sulphurous odour 297 
from day 7 to day 56 was observed, relating to the presence of increasing concentration of 298 
oxidised captopril (captopril disulphide). There was no change in colour of the OLs over 299 
the 56 days. Interestingly, Berger et al
22
 reported the formation of a yellow colour within 300 
three weeks for 1 mg/mL liquid captopril solution prepared in buffered “Ora” preparations 301 
(pH 4.2).
22
  302 
In comparison, extemporaneously prepared novel captopril FDTs were stable over a longer 303 
time of at least 56 days for the 10mg FDTs as the captopril was present as a solid. It is 304 
expected that as individually packaged blisters their stability may be further enhanced 305 
making these more convenient for both pharmacists and patients. Due to the amphoteric 306 
nature of captopril, FDTs when administered as oro-dispersible tablets, may facilitate the 307 
absorption of captopril across the lipid membranes of the buccal mucosa and result in 308 
enhanced absorption and reduced bioavailability differences as observed with other 309 
OLs.
8,9,28 
310 
 311 
CONCLUSION 312 
To date, the use of captopril in treating children is unlicensed and the only commercially 313 
available captopril is a tablet formulation licensed for use in adults. As a result patients 314 
receiving captopril (off label) are given an unlicensed liquid preparation or a crushed tablet 315 
dissolved in water. The survey carried out in Irish hospitals showed that 8 hospitals were 316 
dispensing extemporaneous liquid captopril either compounded in-house or procured from 317 
„specials‟ manufacturers. The products used varied in stability and shelf life. The most 318 
commonly used extemporaneous captopril OL was prepared in Keltrol® with an assigned 319 
arbitrary shelf life of 7 days when stored at 2-8
o
C. The results of stability testing of 3 320 
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concentrations of this OL formulation performed in this study demonstrated a 7 day 321 
stability although this was dependent on the frequency of opening the bottle. 322 
In comparison, a novel FDT demonstrated a higher stability without the requirement of 323 
refrigerated storage. Due to its fast dissolving property, these tablets could be directly 324 
administered to suitable paediatric patients or easily reconstituted to captopril OL for 325 
infants or enteral administration. Such a formulation would also facilitate patients receiving 326 
chronic therapy to be maintained on the same formulation for the duration of the treatment 327 
as various captopril OL cannot be assumed to have therapeutic equivalence.
8,9,29
 Such a 328 
solid extemporaneous formulation can therefore result in standardisation of captopril 329 
therapy through its improved stability, homogeneity and ease and flexibility of dose 330 
administration. 331 
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Figure 1 pH of Captopril OL formulations at 1, 2.5 and 10mg/mL in Keltrol® stored at 2-6 418 
o 
C over 56 days. (n=3 +/- SD) 419 
Figure 2 Percent captopril remaining in captopril OLs at 1, 2.5 and 10mg/mL in Keltrol® 420 
stored at 2-6 
o
C over 56 days  (n=3 +/- SD) 421 
Figure 3 Percent captopril remaining in captopril OLs (a) 1 mg/mL, (b) 2.5 mg/mL, (c) 10 422 
mg/mL stored at 2-6 
o
C opened vs unopened. (n=3 +/- SD) 423 
Figure 4 Stability profiles of extemporaneously prepared captopril OLs and FDTs at two 424 
dosage strengths (a) 2.5 mg and (b) 10 mg. (n=3 +/- SD) 425 
 426 
 427 
 * 
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Table I Formulation composition for extemporaneously prepared captopril fast dispersible 
tablets (FDTs) 
Formulation composition/ 
tablet 
2.5 mg captopril FDT 10 mg captopril FDT 
Ground Captopril 25mg tablets 
(Captor®)
 
16 mg 64 mg 
Mannitol 200 (Parteck®) 171.4 mg 123.4 mg 
Kollidon CLSF (5 %w/w) 10 mg 10 mg 
Magnesium stearate (0.5 %w/w) 1 mg 1 mg 
Raspberry flavour (0.8 %w/w) 1.6 mg 1.6 mg 
Total tablet weight (mg) 200 mg  200 mg 
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Table II Physical characteristics of extemporaneous captopril FDTs 
 
 
 
 
 
 
 
 
 
 
 
 
Time (days) Captopril Weight (mg) Hardness 
(N) 
DT (seconds) 
Day 1 2.5 mg 198.16  1.08 75.91  0.72 23.6  1.53 
Day 15 2.5 mg 198.10  0.96  74.11  3.28 19.33  1.53  
Day 56 2.5 mg 198.43  1.88 76.41  2.30 17.67  2.08 
Day 1 10 mg 204.31  2.11 54.54  4.37 32.0  3.46 
Day 15 10 mg 205.20  2.75 53.59  1.79   24.67  3.21  
Day 56 10 mg 203.25  1.10 53.82  7.70 23.67  1.53 
Table 2
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